Notably, 3 out of 5 patients with NSCLC harboring KRAS or NRAS driver mutations responded to patritumab deruxtecan in another trial, despite the small number of cases evaluated [41]. This evidence concerns the gene NRAS and non-small cell lung carcinoma.